CSPC Innovation Pharmaceutical (SHE:300765) subsidiary Megalith Pharmaceutical received breakthrough therapy designation from China's National Medical Products Administration for its SYS6010 investigational drug.
The drug is indicated for patients with driver gene-negative non-squamous non-small cell lung cancer after failing immunotherapy and platinum-based chemotherapy, according to a Tuesday after-hours filing with the Shenzhen bourse.